Back to Results
First PageMeta Content
Chelating agents / Health / Deferasirox / Myelodysplastic syndrome / Iron overload / Deferiprone / Thalassemia / Deferoxamine / Beta-thalassemia / Chemistry / Medicine / Antidotes


Document Date: 2015-03-16 01:05:15

Open Document

File Size: 290,68 KB

Share Result on Facebook

Company

Novartis Pharmaceuticals Australia Pty Ltd / New Zealand Childrens Haematology/ Oncology Group / Exjade NV / The PBAC / Orphan Australia Pty Ltd / Hospira Pty Ltd / ITT / /

Country

Australia / /

Currency

USD / /

Facility

Royal College of Pathologists / /

IndustryTerm

telephone authority / /

MedicalCondition

chronic iron / myelodysplastic syndromes / malignant disease / transfusional hemosiderosis / chronic transfusions / non-malignant disorders / sickle cell disease / thalassemia / malignant haematological diseases / /

MedicalTreatment

oral therapy / /

Organization

Royal College of Pathologists of Australasia / Haematological Society of Australia and New Zealand / /

Position

Governor / /

Product

Exjade / Exjade NV Deferasirox 250 / Desferal / Exjade NV Deferasirox 500 / Units DEFERASIROX Deferasirox 125 / Meeting 3.1 IRON CHELATING AGENTS DEFERASIROX / /

PublishedMedium

the DUSC review / /

Technology

pharmacokinetics / /

URL

http /

SocialTag